Is MacroGenics, Inc. (MGNX) Overvalued?
We dive into why MacroGenics, Inc. (MGNX) could be considered overvalued on 2026-08-18, based on AAII’s Value Score and Grade.Tudor Pop
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States. The company’s product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for the treatment of platinum-resistant ovarian cancer and clear cell gynecologic cancer which has completed phase 1 clinical trial; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload; MGC028, an antibody-drug conjugates (ADC) that targets ADAM9 and delivers a novel TOP1i-based linker-payload for the treatment of solid tumors, which is in phase 1 clinical trials; MGC030, a ADC molecule that targets an undisclosed antigen expressed across several solid tumors, which is in preclinical trials. It is also developing T-cell engager programs. The company has collaborations with TerSera Therapeutics LLC; Incyte Corporation; and Gilead Sciences, Inc. MacroGenics, Inc. was incorporated in 2000 and is headquartered in Rockville, Maryland.
Commentary & Analysis
Why MacroGenics, Inc.’s (MGNX) Stock Is Up 5.97%
As of Thursday, August 13, MacroGenics, Inc.’s MGNX share price has surged by 5.97%, which has investors questioning if this is right time to sell.Jenna Brashear
What You Need to Know About MacroGenics, Inc.'s Q3 Earnings
MacroGenics, Inc.'s fiscal Q3 earnings report was released on Thursday, August 13. Let's dive in to see if (MGNX) missed or beat analyst's expectations.Jenna Brashear
Why MacroGenics, Inc.’s (MGNX) Stock Is Down 7.50%
As of Tuesday, July 28, MacroGenics, Inc.’s MGNX share price has dipped by 7.50%, which has investors questioning if this is right time to buy.Michael Rose
Why MacroGenics, Inc.’s (MGNX) Stock Is Up 7.16%
As of Monday, July 27, MacroGenics, Inc.’s MGNX share price has surged by 7.16%, which has investors questioning if this is right time to sell.Michael Rose
Financial Summary
| Share Statistics | MGNX | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $257.3 | $298.4 | 29% |
|
| Shares Out (Mil) | 63.6 | 54.0 | 53% |
|
| Institutional Ownership | 96.4% | 93.1% | 70% |
|
| Float (Mil) | 57.0 | 41.4 | 50% |
|
| Beta | 1.22 | 0.94 | 72% |
|
| Avg Daily Volume (000s) | 543 | 504 | 60% |
|
| Price Change (52-week) |
146.3% | 62.0% | 95% |
|
| Growth | MGNX | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 7.3% | 14.0% | 47% |
|
| Net Income (5yr) | 10.5% | (10.0%) | 56% |
|
| EPS (5yr) | 13.7% | 16.0% | 53 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (31.4%) | (15.6%) | 18% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 3 | 1 | 2 | |
| Current EPS | ($0.270) | ($0.740) | ($1.140) | |
| Month Ago EPS | ($0.313) | $0.035 | ($1.413) | |
| # Rev Up | 0 | 0 | 0 | |
| # Rev Down | 1 | 1 | 1 | |
| Three Months Ago EPS | ($0.313) | $0.035 | ($1.413) | |
| Year/Year Chg | (75.5%) | (37.4%) | 47.2% | |
| Financials | MGNX | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $175 | $37 | 31% |
|
| Net Income (TTM) (Mil) | ($15) | ($43) | 26% |
|
| EPS (TTM) | ($0.230) | ($1.400) | 33% |
|
| Operating Cash Flow (TTM) (Mil) | ($64) | ($32) | 8% |
|
| Net Cash Flow (TTM) (Mil) | ($17) | $2 | 27% |
|
| Long-Term Debt (Q1) (Mil) | $30 | $4 | 35% |
|
| Enterprise Value (Q1) (Mil) | $131 | $186 | 23% |
|
| Valuation | MGNX | Industry Median |
Percentile (All Stocks) |
|
| P/B | 6.03 | 2.89 | 82% |
|
| P/E | na | 19.9 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | MGNX | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | (0.7%) | 64.6% | 4% |
|
| Net Margin | (8.3%) | (75.3%) | 22% |
|
| ROA | (4.9%) | (47.6%) | 30% |
|
| ROE | (32.6%) | (55.0%) | 19% |
|
| Liabilities to Assets | 87.6% | 29.5% | 81% |
|
| F-Score | 4 | 3 | 33% |
|
Passing Stock Screens
As of 8/26/2026, from a list of 60 stock screening strategies,
GURU STRATEGY
O'Shaughnessy: Growth Screen II
Factors: Value, Momentum
O'Shaughnessy tries to predict the future using historical long-term trends.
| Performance Since Inception: | 15.1% |
| +/- S&P 500: | +7.6 |
